Dr. Friedman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
94 Old Short Hills Rd
# Saint
Livingston, NJ 07039Phone+1 973-322-5691Fax+1 973-322-5504
Education & Training
- NYU Grossman School of MedicineFellowship, Pediatric Cardiology, 1980 - 1983
- Jacobi Medical Center/Albert Einstein College of MedicineResidency, Pediatrics, 1977 - 1980
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1977
Certifications & Licensure
- NJ State Medical License 1990 - 2025
- NY State Medical License 1978 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Cardiology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- Westchester Magazine: Top Doctors Castle Connolly, 2010-2013
- New York Magazine: Top Doctors Castle Connolly, 2005-2008
- Join now to see all
Publications & Presentations
PubMed
- 182 citationsMaternal and Fetal Factors Associated With Mortality and Morbidity in a Multi–Racial/Ethnic Registry of Anti-SSA/Ro–Associated Cardiac Neonatal LupusPeter M. Izmirly, Amit Saxena, Mimi Y. Kim, Dan Wang, Sara Sahl
Circulation. 2011-11-01 - 24 citationsSerum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro–Associated Cardiac Neonatal LupusAmit Saxena, Peter M. Izmirly, Sung Won Han, Paraskevi Briassouli, Tania L. Rivera
Journal of the American College of Cardiology. 2015-08-25 - 36 citationsCardiac manifestations of neonatal lupus: a review of autoantibody-associated congenital heart block and its impact in an adult population.Christine Capone, Jill P. Buyon, Deborah M. Friedman, William H. Frishman
Cardiology in Review. 2011-12-01
Press Mentions
- Zosano Pharma Corporation (NASDAQ: ZSAN) Soars 171% After Final Milestone Completed in Long-Term Safety Study of Qtrypta, a Acute Treatment for Migraine DiseaseFebruary 21st, 2019
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: